Observing Prolymphocytic Leukemia T
Prospective and Retrospective Study Evaluating Epidemiological, Clinical, Molecular and Therapeutic Data of Prolymphocytic Leukemia T. A FILO Study.
French Innovative Leukemia Organisation · NCT04411043
This study looks at the genetic features of Prolymphocytic Leukemia T in older patients to better understand the disease and how to treat it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | French Innovative Leukemia Organisation (other) |
| Drugs / interventions | alemtuzumab, chemotherapy |
| Locations | 1 site (Le Mans) |
| Trial ID | NCT04411043 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on Prolymphocytic Leukemia T, a rare and aggressive form of leukemia primarily affecting the elderly. It aims to characterize the molecular features of this disease, particularly the genetic rearrangements and mutations associated with it. The study will involve patients diagnosed with Prolymphocytic Leukemia T, who will be monitored to gather data on their condition and response to treatments. The findings may help improve understanding and management of this challenging disease.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and over diagnosed with Prolymphocytic Leukemia T.
Not a fit: Patients who do not have Prolymphocytic Leukemia T or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better treatment strategies and improved outcomes for patients with Prolymphocytic Leukemia T.
How similar studies have performed: While there have been studies on T-cell leukemias, the specific focus on Prolymphocytic Leukemia T and its molecular characterization is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Man or woman aged 18 or over * Patient with prolymphocytic T leukemia Exclusion Criteria: * Absence of signature of informed consent
Where this trial is running
Le Mans
- Chd Le Mans — Le Mans, France (RECRUITING)
Study contacts
- Principal investigator: Kamel LARIBI, Dr — French Innovative Leukemia Organisation
- Study coordinator: Charles HERBAUX, Dr
- Email: Charles.herbaux@chru-lille.fr
- Phone: 3 20 44 57 13
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prolymphocytic Leukemia, T-cell Leukemia